[Construction and expression of a vector containing protein transduction domain and bcr/abl fusion gene].
Yingmin Liang, Qiang Sun, Shanshan Jiang, Jizhu Wang, Rong-Li Wu, Ping Chen, Li Liu, Hua Han
Abstract
Yingmin Liang, Qiang Sun, Shanshan Jiang, Jizhu Wang, Rong-Li Wu, Ping Chen, Li Liu, Hua Han
Abstract
OBJECTIVE: To construct a vector containing protein transduction domain (PTD) and bcr/abl fusion gene of chronic myelogenous leukemia and express PTD-bcr/abl fusion protein in E. Coli. METHODS: DNA fragment encoding PTD was synthesized and fused to PCR-amplified bcr/abl gene fragment, then inserted into plasmid pET-16b to get the expression vector pEPb containing PTD-bcr/abl fusion gene, which was transfected and expressed in E. Coli LB21. PTD-bcr/abl fusion protein was purified by affinity chromatography. RESULTS: 523 bp bcr/abl fusion gene was effectively amplified. The PTD-bcr/abl gene sequencing showed the same sequence as scheduled. The fusion peptide was successfully expressed in E. Coli and purified. CONCLUSION: The results may provide a new PTD-bcr/abl fusion peptide for the immunotherapy of CML.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: To construct a vector containing protein transduction domain (PTD) and bcr/abl fusion gene of chronic myelogenous leukemia and express PTD-bcr/abl fusion protein in E. Coli. METHODS: DNA fragment encoding PTD was synthesized and fused to PCR-amplified bcr/abl gene fragment, then inserted into plasmid pET-16b to get the expression vector pEPb containing PTD-bcr/abl fusion gene, which was transfected and expressed in E. Coli LB21. PTD-bcr/abl fusion protein was purified by affinity chromatography. RESULTS: 523 bp bcr/abl fusion gene was effectively amplified. The PTD-bcr/abl gene sequencing showed the same sequence as scheduled. The fusion peptide was successfully expressed in E. Coli and purified. CONCLUSION: The results may provide a new PTD-bcr/abl fusion peptide for the immunotherapy of CML.
Key concepts: Fusion protein, Fusion gene, ABL, breakpoint cluster region, Chronic myelogenous leukemia, Molecular biology, Gene, Transduction (biophysics)